When did Immunoprecise Antibodies report Q1 2026 earnings?

Immunoprecise Antibodies (HYFT) reported Q1 2026 earnings on March 12, 2026 before market open.

What were Immunoprecise Antibodies's Q1 2026 revenue and EPS?

Immunoprecise Antibodies reported revenue of $3.1M and diluted EPS of $-0.06 for Q1 2026.

Revenue missed the consensus estimate of $3.4M by $330.2K. EPS missed the consensus estimate of $-0.04 by $0.02.

Compared to the same quarter a year prior, revenue declined 26.8% from $4.2M a year earlier and diluted EPS grew 0.0% from $-0.06.

Reported March 12, 2026 · Before market open

Revenue estimate$3.4M

EPS estimate-$0.04

Jul 23, 2026 (in a month)

Revenue estimate$3.2M

EPS estimate-$0.05

Q1 2026$3.1MMiss by $330.2K

Q1 2026-$0.06Miss by $0.02

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

When did Immunoprecise Antibodies report Q1 2026 earnings?: Immunoprecise Antibodies (HYFT) reported Q1 2026 earnings on March 12, 2026 before market open.
What were Immunoprecise Antibodies's Q1 2026 revenue and EPS?: Immunoprecise Antibodies reported revenue of $3.1M and diluted EPS of $-0.06 for Q1 2026.
Did Immunoprecise Antibodies beat estimates in Q1 2026?: Revenue missed the consensus estimate of $3.4M by $330.2K. EPS missed the consensus estimate of $-0.04 by $0.02.
How did Immunoprecise Antibodies's Q1 2026 results compare year-over-year?: Compared to the same quarter a year prior, revenue declined 26.8% from $4.2M a year earlier and diluted EPS grew 0.0% from $-0.06.